PRTA -Prothena Corporation plc
PRTA — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
16.24
Margin Of Safety %
Put/Call OI Ratio
0.62
EPS Next Q Diff
1.77
EPS Last/This Y
5.17
EPS This/Next Y
-1.68
Price
10.37
Target Price
21
Analyst Recom
2.17
Performance Q
13.85
Upside
-668.4%
Beta
-0.35
Ticker: PRTA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | PRTA | 9.81 | 0.30 | 0.00 | 6329 |
| 2026-03-10 | PRTA | 9.76 | 0.31 | 0.50 | 6262 |
| 2026-03-11 | PRTA | 9.57 | 0.30 | 0.03 | 6304 |
| 2026-03-12 | PRTA | 9.31 | 0.30 | 35.90 | 6347 |
| 2026-03-13 | PRTA | 9.31 | 0.30 | 14.96 | 6347 |
| 2026-03-17 | PRTA | 9.01 | 0.38 | 0.00 | 6676 |
| 2026-03-18 | PRTA | 8.6 | 0.37 | 0.02 | 6742 |
| 2026-03-19 | PRTA | 8.53 | 0.36 | 0.17 | 6793 |
| 2026-03-20 | PRTA | 8.76 | 0.36 | 0.05 | 6795 |
| 2026-03-23 | PRTA | 8.82 | 0.15 | 0.00 | 4161 |
| 2026-03-24 | PRTA | 8.72 | 0.13 | 43.00 | 4873 |
| 2026-03-25 | PRTA | 9.31 | 0.13 | 16.89 | 4912 |
| 2026-03-26 | PRTA | 9.5 | 0.64 | 0.00 | 7157 |
| 2026-03-27 | PRTA | 9.27 | 0.64 | 0.00 | 7157 |
| 2026-03-30 | PRTA | 9.24 | 0.63 | 0.00 | 7229 |
| 2026-03-31 | PRTA | 9.71 | 0.63 | 0.00 | 7242 |
| 2026-04-01 | PRTA | 10.01 | 0.63 | 0.05 | 7244 |
| 2026-04-02 | PRTA | 9.87 | 0.63 | 0.00 | 7250 |
| 2026-04-06 | PRTA | 10.03 | 0.63 | 0.00 | 7250 |
| 2026-04-07 | PRTA | 10.36 | 0.62 | 10.71 | 7299 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | PRTA | 9.80 | 72.8 | - | 1.23 |
| 2026-03-10 | PRTA | 9.76 | 72.8 | - | 1.23 |
| 2026-03-11 | PRTA | 9.57 | 72.8 | - | 1.23 |
| 2026-03-12 | PRTA | 9.29 | 72.8 | - | 1.23 |
| 2026-03-13 | PRTA | 9.20 | 72.8 | - | 0.64 |
| 2026-03-17 | PRTA | 9.01 | 72.8 | - | 0.64 |
| 2026-03-18 | PRTA | 8.60 | 72.8 | - | 0.64 |
| 2026-03-19 | PRTA | 8.53 | 72.8 | - | 0.64 |
| 2026-03-20 | PRTA | 8.75 | 72.8 | - | 0.64 |
| 2026-03-23 | PRTA | 8.81 | 72.8 | - | 0.64 |
| 2026-03-24 | PRTA | 8.73 | 72.8 | - | 0.64 |
| 2026-03-25 | PRTA | 9.30 | 72.8 | - | 0.64 |
| 2026-03-26 | PRTA | 9.51 | 72.8 | - | 0.64 |
| 2026-03-27 | PRTA | 9.27 | 72.8 | - | 0.64 |
| 2026-03-30 | PRTA | 9.24 | 72.8 | - | 0.64 |
| 2026-03-31 | PRTA | 9.71 | 72.8 | - | 0.64 |
| 2026-04-01 | PRTA | 10.01 | 72.8 | - | 0.64 |
| 2026-04-02 | PRTA | 9.87 | 72.8 | - | 0.64 |
| 2026-04-06 | PRTA | 10.02 | 72.8 | - | 0.64 |
| 2026-04-07 | PRTA | 10.37 | 72.8 | - | 0.64 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | PRTA | 0.00 | 5.78 | 16.32 |
| 2026-03-10 | PRTA | 0.00 | 5.78 | 16.32 |
| 2026-03-11 | PRTA | 0.00 | 5.78 | 15.80 |
| 2026-03-12 | PRTA | 0.00 | 5.78 | 15.80 |
| 2026-03-13 | PRTA | 0.00 | 5.78 | 15.80 |
| 2026-03-17 | PRTA | 0.00 | 5.75 | 15.80 |
| 2026-03-18 | PRTA | 0.00 | 5.75 | 15.80 |
| 2026-03-19 | PRTA | 0.00 | 5.75 | 15.80 |
| 2026-03-20 | PRTA | 0.00 | 5.75 | 15.80 |
| 2026-03-23 | PRTA | 0.00 | 5.76 | 15.80 |
| 2026-03-24 | PRTA | 0.00 | 5.76 | 15.80 |
| 2026-03-25 | PRTA | 0.00 | 5.76 | 16.24 |
| 2026-03-26 | PRTA | 0.00 | 5.76 | 16.24 |
| 2026-03-27 | PRTA | 0.00 | 5.76 | 16.24 |
| 2026-03-30 | PRTA | 0.00 | 5.73 | 16.24 |
| 2026-03-31 | PRTA | 0.00 | 5.73 | 16.24 |
| 2026-04-01 | PRTA | 0.00 | 5.73 | 16.24 |
| 2026-04-02 | PRTA | 0.00 | 5.73 | 16.24 |
| 2026-04-06 | PRTA | 0.00 | 5.78 | 16.24 |
| 2026-04-07 | PRTA | 0.00 | 5.78 | 16.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.44
Avg. EPS Est. Current Quarter
-0.3
Avg. EPS Est. Next Quarter
1.32
Insider Transactions
Institutional Transactions
5.78
Beta
-0.35
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
35
Fair Value
Quality Score
18
Growth Score
26
Sentiment Score
57
Actual DrawDown %
87
Max Drawdown 5-Year %
-94.2
Target Price
21
P/E
Forward P/E
PEG
P/S
57.61
P/B
1.99
P/Free Cash Flow
EPS
-4.53
Average EPS Est. Cur. Y
0.64
EPS Next Y. (Est.)
-1.04
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2520.57
Relative Volume
0.93
Return on Equity vs Sector %
-114.5
Return on Equity vs Industry %
-97.9
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.11
EBIT Estimation
◆
PRTA
Healthcare
$10.36
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
66.3
Range 1M
97.4%
Sup Dist
4.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
105.5%
EPS NY
-435.1%
52W%
80.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+102.7% upside
Upside
+102.7%
Quality
18
Prothena Corporation plcSector: Healthcare
Industry: Biotechnology
Employees: 67
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
PRTA
Latest News
—
Caricamento notizie per PRTA…
stock quote shares PRTA -Prothena Corporation plc Stock Price stock today
news today PRTA -Prothena Corporation plc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRTA -Prothena Corporation plc yahoo finance google finance
stock history PRTA -Prothena Corporation plc invest stock market
stock prices PRTA premarket after hours
ticker PRTA fair value insiders trading